1. To bring the latest advances and state-of- the- art opportunities for cancer treatment and cancer control trials to patients living in the metropolitan Seattle area, and to smaller communities in Eastern and Western Washington, Alaska and Idaho. This will be done through our component institutions at these locations, including Valley Medical Center (Renton, WA), Evergreen Medical Center (Kirkland, WA), Olympic Memorial Hospital (Port Angeles, WA), Providence Medical Center (Anchorage, AK), Fairbanks Memorial Hospital (Fairbanks, AK), and the North Idaho Cancer Center (Coeur d'Alene, ID) and the providers who practice in these hospitals. 2. To seek ways of increasing the participation of women and minorities in cancer trials, particularly cancer control and prevention trials, by reaching out to Native Americans, the Asian and African American communities, both in Washington state and Alaska. 3. To maintain and hopefully increase accrual to CCOP protocols in both treatment and cancer control and prevention. 4. To contribute to the scientific administrative affairs of each research base by active participation in their meetings, committees and publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035192-26S1
Application #
8117966
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Kelaghan, Joseph
Project Start
1983-09-01
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2011-05-31
Support Year
26
Fiscal Year
2010
Total Cost
$487,529
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
076647908
City
Seattle
State
WA
Country
United States
Zip Code
98101
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42

Showing the most recent 10 out of 131 publications